Who is sponsoring NCT00670501?

NCT00670501 is sponsored by Eli Lilly and Company.

What condition does NCT00670501 study?

NCT00670501 studies Osteoporosis, Postmenopausal.

What drugs are being tested in NCT00670501?

Interventions: teriparatide, teriparatide, Placebo, Calcium Supplement, Vitamin D Supplement.

What is the status of NCT00670501?

NCT00670501 is currently COMPLETED.

Last reviewed 2008-04-29 · How we verify

Effects of LY333334 in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670501 Phase 3 COMPLETED

The primary objective of this study is to demonstrate a reduction in the proportion of new vertebral fractures in postmenopausal women with osteoporosis following 3-years of treatment with 20 and 40 mcg/day of teriparatide plus calcium and vitamin D compared with calcium and vitamin D alone.

Details

Lead sponsor	Eli Lilly and Company
Phase	Phase 3
Status	COMPLETED
Enrolment	1637
Start date	1996-08
Completion	1999-04

Conditions

Osteoporosis, Postmenopausal

Interventions

teriparatide
teriparatide
Placebo
Calcium Supplement
Vitamin D Supplement

Primary outcomes

To demonstrate a reduction in the proportion of patients with new vertebral fractures (by spinal x-ray) following 3-year treatment with 20 and 40 micrograms/day of LY333334 plus calcium and vitamin D compared with calcium and vitamin D alone. — Baseline, randomization, 24 , 36, and 60 months

Countries

United States, Argentina, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Sweden